[1]刘 超,刘 楠,吴 航,等.利拉鲁肽对急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后无复流和心功能的影响[J].陕西医学杂志,2022,51(10):1294-1297,1312.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.029]
　LIU Chao,LIU Nan,WU Hang,et al.Effects of liraglutide on no-reflow and cardiac function in STEMI patients after PCI[J].,2022,51(10):1294-1297,1312.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.029]
点击复制

利拉鲁肽对急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后无复流和心功能的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年10期
页码:
1294-1297,1312
栏目:
药物与临床
出版日期:
2022-10-05

文章信息/Info

Title:
Effects of liraglutide on no-reflow and cardiac function in STEMI patients after PCI
作者:
刘 超1; 刘 楠1; 吴 航1; 张新彧2
(1.铜川矿务局中心医院,陕西 铜川 727000; 2.西电集团医院急诊科,陕西 西安 710077)
Author(s):
LIU Chao; LIU Nan; WU Hang; ZHANG Xinyu
(Tongchuan Mining Bureau Central Hospital,Tongchuan 727000,China)
关键词:
利拉鲁肽;  急性ST段抬高型心肌梗死;  完全灌注;  无复流;  心功能;  危险因素
Keywords:
Liraglutide;  Acute ST-segment elevation myocardial infarction;  Full perfusion;  No-reflow;  Cardiac function;  Risk factors
分类号:
R 542.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.10.029
文献标志码:
A
摘要:
目的:探究利拉鲁肽对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入(PCI)术后无复流和心功能的影响。方法:纳入STEMI患者182例,按照随机数字表法分为对照组和利拉鲁肽组,各91例。对照组使用常规治疗,利拉鲁肽组在对照组的基础上使用利拉鲁肽。比较两组的无复流率,治疗前后的心功能。根据患者PCI术后是否发生无复流,分为完全灌注组和无复流组,分析两组吸烟史、高血压、肥胖、病变血管数等资料,二元Logistic回归对STEMI患者PCI术后无复流的危险因素进行分析。结果:对照组的无复流率明显高于利拉鲁肽组,差异具有统计学意义(P<0.05)。治疗后,对照组和利拉鲁肽组患者的左心室射血分数(LVEF)增加,左室舒张末期内径(LVEDD)、左室收缩末期容积(LVESV)下降,其中利拉鲁肽组改善更明显,两组比较差异具有统计学意义(均P<0.05)。年龄、超敏C反应蛋白(hs-CRP)均为STEMI患者PCI术后无复流的危险因素,利拉鲁肽治疗为保护性因素(均P<0.05)。结论:利拉鲁肽可有效降低STEMI患者PCI术后无复流发生风险,并可促使患者心功能的改善。
Abstract:
Objective:To investigate the effects of liraglutide on no-reflow and cardiac function in patients with acute ST-segment elevation myocardial infarction(STEMI)after percutaneous coronary intervention(PCI).Methods:A total of 182 patients with STEMI were included,and they were divided into control group(91 cases)and liraglutide group(91 cases)by using random number table method.Traditional therapy such as antiplatelet was used in the control group,and liraglutide was used on the basis of the control group in the liraglutide group.The no-reflow rate and cardiac function were compared between the control group and liraglutide group.Patients were divided into complete perfusion group and no-reflow group according to whether no-reflow occurred after PCI,and the data of smoking history,hypertension,obesity and number of diseased vessels were analyzed.The risk factors affecting no-reflow after PCI in STEMI patients were analyzed by binary Logistic regression.Results:Compared with the liraglutide group,the no-reflow rate in the control group was significantly higher(P<0.05).After treatment,the LVEF of the two groups increased significantly,while the LVEDD and LVESV decreased significantly,and the liraglutide group improved more significantly(all P<0.05).Age and hs-CRP were risk factors for no-reflow after PCI in STEMI patients,and liraglutide treatment was a protective factor(all P<0.05).Conclusion:Liraglutide can effectively reduce the risk of no-reflow after PCI in STEMI patients,and may help to improve cardiac function in patients.

参考文献/References:

[1] 孙 冰,王海昌,孙冬冬.急性ST段抬高型心肌梗死溶栓治疗的最新进展[J].心脏杂志,2020,32(1):93-98.
[2] 周莹峰.阿托伐他汀对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后无复流现象的作用[J].实用临床医药杂志,2019,23(2):40-43.
[3] 蔺建蕊,崔向丽,米东华,等.新型降糖药物对2型糖尿病患者心脑血管事件影响的研究进展[J].中国卒中杂志,2021,16(7):739-745.
[4] Kajiwara M,Tanaka A,Kawasaki T,et al.Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction:A non-randomized interventional pilot trial[J].J Cardiol,2017,69(3):511-517.
[5] 来 静,李 娜,李 超.利拉鲁肽对脂多糖诱导大鼠肺微血管内皮细胞PI3K/Akt信号通路的影响[J].陕西医学杂志,2021,50(8):921-924.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
[7] 曹春晖,王 蓉,高登峰,等.愈梗通瘀汤联合西药治疗急性心肌梗死疗效及对患者血液流变学指标和心功能的影响[J].陕西中医,2021,42(10):1382-1384.
[8] 郑士航,张飞飞,高 曼,等.急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后无复流的研究进展[J].国际心血管病杂志,2022,49(1):32-35.
[9] 纪立伟,郭立新.胰高糖素样肽-1类药物的心血管保护作用[J].中华糖尿病杂志,2020,12(8):654-660.
[10] 杨 燕,杨晋静,徐继尧,等.利拉鲁肽对急性心肌梗死早期心脏功能的影响研究[J].中国药物与临床,2021,21(1):1-4.
[11] Chen WR,Chen YD,Tian F,et al.Effects of liraglutide on reperfusion injury in patients with ST-Segment-elevation myocardial infarction[J].Circ Cardiovasc Imaging,2016,9(12):e005146.
[12] 乐 健,何胜虎,胡 梦,等.老年急性ST段抬高型心肌梗死患者冠状动脉介入术后无复流的临床特征及危险因素[J].中华老年心脑血管病杂志,2020,22(12):1263-1267.
[13] 王文静.糖尿病新型药物利拉鲁肽保护心血管相关信号通路概述[J].实用中西医结合临床,2020,20(5):177-179.
[14] 岳晓燕,张大卫.利拉鲁肽在2型糖尿病合并急性ST段抬高型心肌梗死患者PCI术后的应用体会[J].国际医药卫生导报,2018,24(23):3613-3616.
[15] 陈彦霞,张祥建,杨 旸,等.利拉鲁肽促进实验性脑梗死小鼠血管新生及其作用机制的研究[J].脑与神经疾病杂志,2019,27(2):85-89.
[16] 曹 磊,宋新梅,冯克娜,等.利拉鲁肽干预对急性心肌梗死伴2型糖尿病患者心室重构及心功能的影响[J].中华内分泌代谢杂志,2019,35(2):121-127.
[17] 陈兆君.利拉鲁肽联合二甲双胍治疗对2型糖尿病合并冠状动脉粥样硬化性心脏病患者血脂水平、心功能的影响[J].中国药物经济学,2020,15(10):80-83.
[18] 洪建仁,任翠花,姜砚劼,等.利拉鲁肽通过抑制线粒体依赖性凋亡及缺氧诱导因子1α表达对脊髓损伤的保护作用及其机制[J].中国中医骨伤科杂志,2020,28(11):1-5.
[19] 杜优优,姚 瑞,高 路,等.利拉鲁肽对大鼠心肌成纤维细胞调控机制研究[J].中华急诊医学杂志,2020,29(11):1425-1431.
[20] 乔慧瑛,周文青,任海燕,等.利拉鲁肽对急性心肌梗死大鼠心肌纤维化影响的实验研究[J].河北医学,2018,24(10):1585-1589.

相似文献/References:

[1]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(10):518.
[2]李超杰,陈慧敏,濮先明.利拉鲁肽、格列美脲分别联用二甲双胍治疗肥胖型2型糖尿病疗效观察[J].陕西医学杂志,2021,50(3):356.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.026]
　LI Chaojie,CHEN Huimin,PU Xianming.Efficacy of lilarutide and glimepiride combined with metformin respectivelyin treatment of obese type 2 diabetes mellitus[J].,2021,50(10):356.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.026]
[3]来 静,李 娜,李 超.利拉鲁肽对脂多糖诱导大鼠肺微血管内皮细胞PI3K/Akt信号通路的影响[J].陕西医学杂志,2021,50(8):921.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.005]
　LAI Jing,Li Na,LI Chao.Effect of liraglutide on PI3K/Akt signaling pathway in rat lung microvascular endothelial cells induced by lipopolysaccharide[J].,2021,50(10):921.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.005]
[4]李 刚,陈 茹,马立云,等.利拉鲁肽通过转换生长因子β1/Smad家族成员3信号通路对糖尿病大鼠心肌损伤和肠道菌群的影响[J].陕西医学杂志,2025,54(4):470.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.007]
　LI Gang,CHEN Ru,MA Liyun,et al.Effects of Liraglutide on myocardial damage and intestinal flora in diabetic rats through TGF-β1/Smad3 signaling pathway[J].,2025,54(10):470.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.007]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2020CF-163)
更新日期/Last Update: 2022-10-07